RedHill Biopharma: Up as independent panel supports COVID-19 drug trial
29/01/2021 12:36
** Israeli drugmaker's U.S.-listed shares RDHL.O up 2.4%
at $9.10 premarket
** Co says an independent data safety monitoring board
recommended continuing RDHL's global mid-to-late-stage trial of
COVID-19 treatment following a pre-scheduled futility review
urn:newsml:reuters.com:*:nPre8KZqya
** Says data from the trial expected in Q2, as well as
potential global emergency use authorization applications
** Up to Thursday's close, stock had risen 56% in the last
12 months
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))